Lenvatinib, a multi-tyrosinase inhibitor with a unique binding mechanism to vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), has exhibited outstanding antitumor effectiveness and safety in the first-line treatment of unresectable HCC (6). The gene discussed is TYR; the disease is hepatocellular carcinoma.